Immune‐related adverse events in urothelial cancer patients: Adjustment for immortal time bias

To investigate the association between the onset, severity, and type of immune‐related adverse events (irAEs) and the efficacy of pembrolizumab in patients with platinum‐pretreated advanced urothelial carcinoma (UC), we retrospectively collected clinical datasets of 755 patients and conducted landma...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuka, Hikari, Kita, Yuki, Ito, Katsuhiro, Sano, Takeshi, Inokuchi, Junichi, Tomida, Ryotaro, Takahashi, Atsushi, Matsumoto, Kazumasa, Kurahashi, Ryoma, Ozaki, Yu, Uegaki, Masayuki, Maruyama, Satoru, Mukai, Shoichiro, Tsutsumi, Masakazu, Kawahara, Takashi, Segawa, Takehiko, Kitamura, Hiroshi, Morita, Satoshi, Kobayashi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633286/
https://www.ncbi.nlm.nih.gov/pubmed/35997546
http://dx.doi.org/10.1111/cas.15539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633286/
https://www.ncbi.nlm.nih.gov/pubmed/35997546
http://dx.doi.org/10.1111/cas.15539

Ejemplares similares